Company news

BeyondSpring, Inc. news in 2025

BeyondSpring, Inc.'s news releases, calls and decks from 2025, newest first.

View company

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path

December 12, 2025

BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025

December 11, 2025

BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update

November 12, 2025

BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment

August 13, 2025

BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure

July 7, 2025

BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting

June 3, 2025

BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting

May 28, 2025

BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025

BeyondSpring Files 2024 Annual Report on Form 10-K

March 27, 2025

BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones

March 27, 2025

2024 Full Year Financial Report

March 26, 2025

BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies

January 27, 2025

Decks in 2025